Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

Mancini, D. P., & Smyth, J. (2022, February 16). Merck struggles to win European approval for Covid-19 antiviral pill. Financial Times. https://www.ft.com/content/2cf0b6cc-b07b-4ff9-a833-42eb1798a576

Academics: Viral Evolution Scenarios, 10 February 2022. (n.d.). GOV.UK. Retrieved February 14, 2022, from https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022

Couzin-Frankel, J. (2021). Antiviral pills could change pandemic’s course. Science, 374(6569), 799–800. https://doi.org/10.1126/science.acx9605

Hoffmann, M., Mösbauer, K., Hofmann-Winkler, H., Kaul, A., Kleine-Weber, H., Krüger, N., Gassen, N. C., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 1–5. https://doi.org/10.1038/s41586-020-2575-3

Zhang, S. (2020, April 8). The Best Hopes for a Coronavirus Drug. The Atlantic. https://www.theatlantic.com/science/archive/2020/04/what-coronavirus-drug-will-look-like/609661/

Lipsitch, M., Perlman, S., & Waldor, M. K. (2020). Testing COVID-19 therapies to prevent progression of mild disease. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30372-8

Mullard, A. (2020). Flooded by the torrent: The COVID-19 drug pipeline. The Lancet, 395(10232), 1245–1246. https://doi.org/10.1016/S0140-6736(20)30894-1